Intrinsiqq
Cadrenal Therapeutics Inc. logo

Cadrenal Therapeutics Inc. Insider Trading

CVKD

Compare
Last 12 months

Insiders sold 458K and bought nothing on the open market.

All of the selling was scheduled in advance under 10b5-1 plans. The last open-market buy by an executive or director was in Oct 2023.

Net open-market
−458K
0 buys · 11 sales
Under a 10b5-1 plan
100%
of the value sold
Insiders who bought / sold
0 / 2
executives and directors
Last open-market buy
Oct 2023
Oct 5, 2023

Get an email when CVKD's executives or directors buy, or make a large sale outside a plan.

Trades · last 2 years

  • Jun 2910b5-1 plan
    Quang X Pham
    Chairman and CEO · sold 7,400 at $3.03
    22K
    2.4% of stake
  • Jun 25 – 2610b5-1 plan
    Quang X Pham
    Chairman, CEO and Interim CFO · sold 11,156 at avg $3.04
    34K
    3.5% of stake
  • Jun 22 – 2310b5-1 plan
    Quang X Pham
    Chairman, CEO and Interim CFO · sold 11,444 at avg $3.48
    40K
    3.5% of stake
  • Jun 16 – 1710b5-1 plan
    Quang X Pham
    Chairman, CEO and Interim CFO · sold 4,126 at avg $3.18
    13K
    1.2% of stake
  • Jun 11 – 1510b5-1 plan
    Quang X Pham
    Chairman, CEO and Interim CFO · sold 18,124 at avg $3.88
    70K
    5.2% of stake
  • Jun 8 – 1010b5-1 plan
    Quang X Pham
    Chairman, CEO and Interim CFO · sold 22,385 at avg $4.17
    93K
    6.0% of stake
  • Jun 3 – 510b5-1 plan
    Quang X Pham
    CEO and Chairman · sold 8,285 at avg $4.37
    36K
    2.2% of stake
  • May 29 – Jun 210b5-1 plan
    Quang X Pham
    CEO and Chairman · sold 652 at avg $4.72
    3K
    0.2% of stake
  • May 11 – 2810b5-1 plan
    Quang X Pham
    CEO and Chairman · sold 12,763 at avg $5.44
    69K
    3.2% of stake
  • May 2210b5-1 plan
    Quang X Pham
    CEO and Chairman · sold 1,165 at $5.69
    7K
    0.5% of stake
  • Dec 29, 202510b5-1 plan
    Matthew K Szot
    Chief Financial Officer · sold 9,933 at $6.97
    69K
    100% of stake
  • Oct 24, 2025 – Oct 27, 202510b5-1 plan
    Matthew K Szot
    Chief Financial Officer · sold 3,600 at avg $13.99
    50K
    27% of stake
  • Oct 24, 2025 – Oct 27, 202510b5-1 plan
    Quang X Pham
    CEO and Chairman · sold 2,444 at avg $14.01
    34K
    0.6% of stake
  • Oct 9, 2025 – Oct 13, 202510b5-1 plan
    Quang X Pham
    CEO and Chairman · sold 3,600 at avg $14.09
    51K
    0.9% of stake
  • Oct 9, 2025 – Oct 13, 202510b5-1 plan
    Matthew K Szot
    Chief Financial Officer · sold 3,493 at avg $14.03
    49K
    21% of stake
  • Oct 6, 202510b5-1 plan
    Matthew K Szot
    Chief Financial Officer · sold 107 at $13.99
    1K
    0.6% of stake
  • Oct 2, 202510b5-1 plan
    Quang X Pham
    CEO and Chairman · sold 500 at $14.13
    7K
    0.1% of stake
  • Sep 29, 2025 – Oct 1, 202510b5-1 plan
    Matthew K Szot
    Chief Financial Officer · sold 1,800 at avg $13.99
    25K
    9.5% of stake
  • Sep 29, 2025 – Oct 1, 202510b5-1 plan
    Quang X Pham
    CEO and Chairman · sold 1,300 at avg $14.01
    18K
    0.3% of stake
  • Sep 24, 2025 – Sep 25, 202510b5-1 plan
    Matthew K Szot
    Chief Financial Officer · sold 12,400 at avg $14.04
    174K
    40% of stake
  • Sep 24, 2025 – Sep 25, 202510b5-1 plan
    Quang X Pham
    CEO and Chairman · sold 9,371 at avg $14.06
    132K
    2.3% of stake
  • Aug 27, 2025 – Aug 28, 202510b5-1 plan
    Matthew K Szot
    Chief Financial Officer · sold 2,000 at avg $14.00
    28K
    6.0% of stake
  • Aug 27, 2025 – Aug 28, 202510b5-1 plan
    Quang X Pham
    CEO and Chairman · sold 5,029 at avg $13.99
    70K
    1.2% of stake
How to read this. Insiders sell for many reasons: taxes, diversifying, a house. Open-market buys are rarer and say more. A 10b5-1 plan is a trading schedule set up months in advance, so those sales were not timed on news. Large holders (funds and 10% owners) are listed under Everything but not counted as insiders. If you own or watch CVKD, we send a push when an executive buys or makes a large sale outside a plan.

Source: SEC Form 4 filings, filed within two business days of each trade and checked for new ones every hour.

Peers

Pharmaceutical Preparations · Pick stocks to compare with CVKD

CompareIntrinsic value
JUNSJupiter Neurosciences Inc.
$1.24-15.41%10
MTNBMatinas Biopharma Holdings Inc.
$0.80-1.23%40
TRAWTraws Pharma Inc.
$0.18-23.91%40
LIXTLixte Biotechnology Holdings Inc.
$2.26-20.88%0
CNTBConnect Biopharma Holdings Ltd.
$0.59-6.05%10
ATNMActinium Pharmaceuticals Inc.
$1.05-1.87%30
GNLXGenelux Corp.
$2.17-4.82%10
NRXPNRx Pharmaceuticals, Inc.
$2.15-15.69%14

Spot a number that looks wrong? Check it in CVKD's SEC filings or

Download this analysis as a PDF (Pro)

Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.

5 of 5 free stocks used today

Keep analysing CVKD

A free account gives you 10 stocks a day, a watchlist and price alerts.

Already have an account?

Or come back tomorrow. Stocks on your watchlist are always free to view.

MarketsPrivacyTerms© 2026 Intrinsiqq

Not financial advice. Analytical data for research only.

Intrinsiqq is a Netherlands-based company operating in Rotterdam, KvK 73238007.